Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel trevatide - Angiochem

Next Previous
X
Search
Drug Profile

Paclitaxel trevatide - Angiochem

Alternative Names: ANG-1005; Angiopep peptide + paclitaxel conjugate – Angiochem; Angiopep-2 paclitaxel conjugate - Angiochem; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem; Paclitaxel-AngioPep1-conjugate-Angiochem; SNG 1005

Latest Information Update: 07 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Brain metastases
  • Phase II Glioblastoma; Glioma

Most Recent Events

  • 07 Sep 2022 Phase-III clinical trials in Brain metastases in USA (IV) (Angiochem website, September 2022)
  • 05 Aug 2019 Innovent Biologics enters into a collaboration agreement with Shenogen Pharma Group for Cancer (Combination therapy, Late-stage disease)
  • 29 May 2019 The National Medical Products Administration approves an IND for a phase II/III trial in Brain metastases (in patients with HER2-negative breast cancer) in China (9272559; 9272205)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top